Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.
Jiangsu Hengrui Pharmaceuticals has declared a final ordinary cash dividend for the year ended 31 December 2025, set at RMB 2 per 10 shares for its H-shareholders, following approval on 16 April 2026. The Hong Kong default payment will be HKD 2.2828 per 10 shares, based on an exchange rate of RMB 1 to HKD 1.14141.
The ex-dividend date is scheduled for 29 April 2026, with the record date set as 11 May 2026 and payment due on 27 May 2026, after a book closure from 4 to 11 May. The announcement also outlines differentiated withholding tax treatment, including a 10% rate for most non-resident and Northbound investors and 20% for certain Southbound individual investors, clarifying after-tax proceeds for various shareholder groups.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company whose H shares are listed in Hong Kong. It operates in the healthcare sector, focusing on the research, development and manufacture of branded prescription drugs for domestic and international markets, with its Class H shares accessible to global investors via the Hong Kong Stock Exchange.
Average Trading Volume: 3,291,704
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$438.2B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.